S&P 500   3,801.17
DOW   30,939.49
QQQ   316.87
S&P 500   3,801.17
DOW   30,939.49
QQQ   316.87
S&P 500   3,801.17
DOW   30,939.49
QQQ   316.87
S&P 500   3,801.17
DOW   30,939.49
QQQ   316.87
Log in
NASDAQ:LGND

Ligand Pharmaceuticals Stock Forecast, Price & News

$129.21
+5.87 (+4.76 %)
(As of 01/19/2021 03:04 PM ET)
Add
Compare
Today's Range
$124.82
Now: $129.21
$131.50
50-Day Range
$83.44
MA: $98.20
$122.28
52-Week Range
$57.24
Now: $129.21
$127.80
Volume17,335 shs
Average Volume318,720 shs
Market Capitalization$2.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.46
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Ligand Pharmaceuticals logo

MarketRank

Overall MarketRank

1.62 out of 5 stars

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500
Employees115

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120.28 million
Cash Flow$6.95 per share
Book Value$43.68 per share

Profitability

Net Income$629.30 million

Miscellaneous

Market Cap$2.08 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$129.21
+5.87 (+4.76 %)
(As of 01/19/2021 03:04 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

How has Ligand Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LGND stock has increased by 41.4% and is now trading at $129.81.
View which stocks have been most impacted by COVID-19
.

Is Ligand Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ligand Pharmaceuticals stock.
View analyst ratings for Ligand Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Ligand Pharmaceuticals?

Wall Street analysts have given Ligand Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ligand Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Ligand Pharmaceuticals
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its quarterly earnings results on Friday, October, 30th. The biotechnology company reported $1.04 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.98 by $0.06. The biotechnology company had revenue of $41.90 million for the quarter, compared to the consensus estimate of $45.09 million. Ligand Pharmaceuticals had a negative net margin of 11.23% and a positive return on equity of 5.90%. The company's revenue was up 69.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.49 EPS.
View Ligand Pharmaceuticals' earnings history
.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Friday, October, 30th. The company provided earnings per share (EPS) guidance of 3.95-3.95 for the period, compared to the Thomson Reuters consensus estimate of $3.91. The company issued revenue guidance of $170-170 million, compared to the consensus revenue estimate of $170.22 million.

What price target have analysts set for LGND?

8 brokers have issued 12 month price objectives for Ligand Pharmaceuticals' stock. Their forecasts range from $155.00 to $229.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $186.00 in the next twelve months. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for Ligand Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Ligand Pharmaceuticals' key competitors?

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the following people:
  • Mr. John L. Higgins, CEO & Exec. Director (Age 50, Pay $945.88k)
  • Mr. Matthew W. Foehr, Pres & COO (Age 47, Pay $847.27k)
  • Mr. Matthew E. Korenberg, Exec. VP of Fin. & CFO (Age 45, Pay $659.07k)
  • Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 51, Pay $571.1k)
  • Patrick O'Brien, Sr. VP of Investor Relations
  • Mr. Todd Pettingill, Director of Corp. Devel.
  • Ms. Audrey Warfield-Graham, Sr. VP of HR
  • Dr. Keith Marschke, Sr. VP of Biology & Scientific Affairs
  • Dr. Vincent D. Antle, Sr. VP of Technical Operations & QA - Capitsol (Age 51)
  • Mr. Patrick Lucy, Sr. VP & CBO Protein Expression Bus.

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, Matthew W Foehr and Sunil Patel.
View institutional ownership trends for Ligand Pharmaceuticals
.

Which institutional investors are selling Ligand Pharmaceuticals stock?

LGND stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, and Matthew W Foehr.
View insider buying and selling activity for Ligand Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $129.81.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $2.09 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 115 workers across the globe.

What is Ligand Pharmaceuticals' official website?

The official website for Ligand Pharmaceuticals is www.ligand.com.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.